Evidence map›Paper›PMID 34658441›Full record

ReviewMissouri medicine

A Primer on Chimera Associated Receptor T-Cells.

Sumalatha Muthineni, Katelyn Zink, Suman Kambhampati

Open access · greenAbstract readReview
In one paragraph

Review in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sumalatha MuthineniInternal Medicine, Hematology/Oncology, practice at the Sarah Cannon Transplant and Cellular Therapy Program, Research Medical Center, Kansas City, Missouri.
Katelyn ZinkHematology/Oncology, practice at the Sarah Cannon Transplant and Cellular Therapy Program, Research Medical Center, Kansas City, Missouri.
Suman KambhampatiHematology/Oncology, practice at the Sarah Cannon Transplant and Cellular Therapy Program, Research Medical Center, Kansas City, Missouri.
Research Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer continues to be one of the leading causes of death. Although survival rates have improved with current treatments for hematological malignancies, relapsed and refractory cases have poor prognosis. Immunotherapy against cancer cells offer new hope for curative response in these patients. Of those, Chimeric Antigen Receptor (CAR) T-cells are emerging as promising therapy for hematological malignancies, where T-lymphocytes are genetically engineered with CAR to recognize and eliminate specific tumor cells. The efficacy of CAR T-cell therapy is also being studied in solid tumors. In this review, the basic principles of CAR T-cell therapy are discussed.

Indexed as

NeoplasmsT-LymphocytesHumansImmunotherapyImmunotherapy, AdoptiveReceptors, Chimeric AntigenReceptors, Chimeric Antigen

Identifiers

PMID34658441
PMCPMC8504496
OpenAlexW3205147556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.